WASHINGTON (AP) — FDA OK: The Food and Drug Administration on Monday approved the drug Zytiga for a new group of prostate cancer patients who have not yet received chemotherapy.
FAMILIAR FACE: The FDA previously approved the pill from Johnson & Johnson for men with prostate cancer who have already taken the chemotherapy drug docetaxel.
Recommended Stories
HALTING HORMONES: Zytiga works be decreasing the male hormone testosterone, which spurs growth of prostate tumors.
